CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 512 enrolled
Drug / intervention
Pandemic influenza vaccine (GSK1119711A)-formulation 1 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00430521
NCT00430521Phase 2Completed
CompareCT.gov

Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules

GlaxoSmithKline·interventional·Posted Feb 2, 2007·Updated Oct 28, 2019

In Brief

A Phase 2 clinical trial evaluating Pandemic influenza vaccine (GSK1119711A)-formulation 1 and Pandemic influenza vaccine (GSK1119711A)-formulation 2 for Influenza and Influenza Vaccines. Completed, enrolled 512 participants across 10 sites.

Detailed Summary

The aim of the study is to assess the safety \& immunogenicity of a pandemic influenza vaccine administered at 2 different time points. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Influenza Vaccines
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2, 2007
Enrollment StartFeb 5, 2007
Primary CompletionOct 20, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.4 years ago

Interventions

Pandemic influenza vaccine (GSK1119711A)-formulation 1biological

2 or 3 doses, intramuscular injection, at different time points.

Pandemic influenza vaccine (GSK1119711A)-formulation 2biological

2 or 3 doses, intramuscular injection, at different time points.